162 related articles for article (PubMed ID: 35267501)
1. Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program.
Pellerino A; Soffietti R; Bruno F; Manna R; Muscolino E; Botta P; Palmiero R; Rudà R
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267501
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
3. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
4. Activity of capecitabine for central nervous system metastases from breast cancer.
Gouveia MC; Hidalgo Filho CM; Moreno RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
[TBL] [Abstract][Full Text] [Related]
5. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
Front Oncol; 2020; 10():271. PubMed ID: 32195186
[No Abstract] [Full Text] [Related]
7. The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Chilà G; Guarini V; Galizia D; Geuna E; Montemurro F
Drug Des Devel Ther; 2021; 15():2711-2720. PubMed ID: 34188449
[TBL] [Abstract][Full Text] [Related]
8. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study.
Gui X; Li H; Yan Y; Zhang R
Oncol Lett; 2020 Dec; 20(6):378. PubMed ID: 33154776
[TBL] [Abstract][Full Text] [Related]
10. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
[TBL] [Abstract][Full Text] [Related]
11. Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Cunningham N; Shepherd S; Mohammed K; Lee KA; Allen M; Johnston S; Kipps E; McGrath S; Noble J; Parton M; Ring A; Turner NC; Okines AFC
Breast Cancer Res Treat; 2022 Oct; 195(3):333-340. PubMed ID: 35976513
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
13. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Anders CK; Melisko ME; Parsons HA; Cropp AM; Silvestri K; Cotter CM; Componeschi KP; Marte JM; Connolly RM; Moy B; Van Poznak CH; Blackwell KL; Puhalla SL; Jankowitz RC; Smith KL; Ibrahim N; Moynihan TJ; O'Sullivan CC; Nangia J; Niravath P; Tung N; Pohlmann PR; Burns R; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU;
J Clin Oncol; 2019 May; 37(13):1081-1089. PubMed ID: 30860945
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
15. Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.
Chi Y; Shang M; Xu L; Gong H; Tao R; Song L; Zhang B; Yin S; Cong B; Li H
Front Oncol; 2022; 12():811919. PubMed ID: 35251981
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
Collins DM; Conlon NT; Kannan S; Verma CS; Eli LD; Lalani AS; Crown J
Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141894
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
18. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T
Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
